What do we learn from HER2-positive breast cancer genomic profiles?

Patients with a tumor presenting amplification of the HER2 gene are currently proposed trastuzumab (herceptin) and this has greatly changed their outcome. However, a number of HER2-positive cancers show intrinsic or acquired resistance to trastuzumab and there are clear indications that they form a...

Descripción completa

Detalles Bibliográficos
Autor principal: Theillet, Charles
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917015/
https://www.ncbi.nlm.nih.gov/pubmed/20519027
http://dx.doi.org/10.1186/bcr2571
_version_ 1782185040010018816
author Theillet, Charles
author_facet Theillet, Charles
author_sort Theillet, Charles
collection PubMed
description Patients with a tumor presenting amplification of the HER2 gene are currently proposed trastuzumab (herceptin) and this has greatly changed their outcome. However, a number of HER2-positive cancers show intrinsic or acquired resistance to trastuzumab and there are clear indications that they form a heterogeneous group of tumors. A paper in this issue of Breast Cancer Research addresses this heterogeneity at the genomic level.
format Text
id pubmed-2917015
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-29170152010-12-01 What do we learn from HER2-positive breast cancer genomic profiles? Theillet, Charles Breast Cancer Res Editorial Patients with a tumor presenting amplification of the HER2 gene are currently proposed trastuzumab (herceptin) and this has greatly changed their outcome. However, a number of HER2-positive cancers show intrinsic or acquired resistance to trastuzumab and there are clear indications that they form a heterogeneous group of tumors. A paper in this issue of Breast Cancer Research addresses this heterogeneity at the genomic level. BioMed Central 2010 2010-06-01 /pmc/articles/PMC2917015/ /pubmed/20519027 http://dx.doi.org/10.1186/bcr2571 Text en Copyright ©2010 BioMed Central Ltd
spellingShingle Editorial
Theillet, Charles
What do we learn from HER2-positive breast cancer genomic profiles?
title What do we learn from HER2-positive breast cancer genomic profiles?
title_full What do we learn from HER2-positive breast cancer genomic profiles?
title_fullStr What do we learn from HER2-positive breast cancer genomic profiles?
title_full_unstemmed What do we learn from HER2-positive breast cancer genomic profiles?
title_short What do we learn from HER2-positive breast cancer genomic profiles?
title_sort what do we learn from her2-positive breast cancer genomic profiles?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917015/
https://www.ncbi.nlm.nih.gov/pubmed/20519027
http://dx.doi.org/10.1186/bcr2571
work_keys_str_mv AT theilletcharles whatdowelearnfromher2positivebreastcancergenomicprofiles

Ejemplares similares